Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

Revenue$211.6MBeat by $16.4M
EPS$0.92Beat by $0.64
Revenue estimate$195.2M
EPS estimate$0.28

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$205.3M
EPS estimate$0.42

Financials

Q4 2025

Income statement

See full
Revenue$211.6M+21.5%
Gross profit$188.6M+27.4%
Operating income-$3.9M-118%
Net income-$4.1M-127%
EPS (diluted)-$0.07-126%

Balance sheet

See full
Cash & equivalents$129.9M+87.4%
Total debt$41.0M+19.6%
Total equity$1.1B+2.5%
Total assets$1.5B+6.2%

Cash flow

See full
Operating cash flow$19.9M-55.3%
CapEx$427.0K+100%
Free cash flow$19.4M-56.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.85B+42.7%
Enterprise value$2.76B+40.7%
P/S4×+0.9×

Profitability

See full
Gross margin89.6%+1.4pp
Operating margin-8.7%-21.0pp
Net margin-5.4%-16.5pp

Returns & leverage

See full
Return on equity-3.7%-11.2pp
Debt / equity0×0.0×
Current ratio1.9×-0.4×

Segments

By product

See full
Qelbree$80.9M+8.8%
GOCOVRI$38.6M+4.7%
Collaboration revenue (ZURZUVAE)$32.8M—
Royalty, licensing, and other revenues$20.7M+167%
APOKYN$9.6M-52.3%

By segment

See full
Reportable Segment$211.6M+21.5%

Versus estimates

Revenue

Q1 2026$207.7MBeat by $14.8M
Q4 2025$211.6MBeat by $16.4M
Q3 2025$192.1MMiss by $2.6MQ2 2025$165.5MMiss by $2.8MQ1 2025$149.8MBeat by $1.9MQ4 2024$174.2MBeat by $18.9M

Diluted EPS

Q1 2026$0.59Beat by $0.31
Q4 2025$0.92Beat by $0.64
Q3 2025$1.01Beat by $0.19Q2 2025$0.91Beat by $0.44Q1 2025$0.42Beat by $0.04Q4 2024$0.75Beat by $0.29

Ask the moment Supernus Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Supernus Pharmaceuticals report Q4 2025 earnings?
Supernus Pharmaceuticals (SUPN) reported Q4 2025 earnings on February 24, 2026 after market close.
What were Supernus Pharmaceuticals's Q4 2025 revenue and EPS?
Supernus Pharmaceuticals reported revenue of $211.6M and eps of $0.92 for Q4 2025.
Did Supernus Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $195.2M by $16.4M. EPS beat the consensus estimate of $0.28 by $0.64.
How did Supernus Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 21.5% from $174.2M a year earlier and eps grew 22.7% from $0.75.
Where can I find Supernus Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001356576-26-000004) and the 10-K periodic report (0001356576-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.